Inclusion Criteria:
* Age 18-80 years
* Type 1 or type 2 diabetes (diagnosed diabetes for more than 3 months)
* Diagnosed with acute Charcot foot defined as a unilateral red, swollen and warm foot, with a difference of skin temperature of more than 2 °C compared with the unaffected foot and with sign of Charcot on either x-rays of the foot, MRI, bone scintigram or PET/CT.
* Peripheral neuropathy: Previously diagnosed and/or biothesiometri: \> 25 V or lack of sensation of 10 grams monofilament on 1. toe at the acute Charcot foot.
Exclusion Criteria:
* Duration of the acute Charcot foot for more than 3 months (at the screening visit).
* Existing foot ulcer on the affected foot
* Previous acute or chronic Charcot of the affected foot
* Planned surgery on the acute Charcot foot
* Infection (cellulitis or osteomyelitis) of the affected foot (clinically and/or radiologically proven)
* Previous midfoot or proximal to mid foot amputation of the affected foot
* Hypocalcemia (Serum Calcium \<2.1 mmol/L or Calcium ion \< 1.12 mmol/L)
* Vitamin D deficiency (Serum 25-hydroxyvitamin D \< 50 nmol/L)
* Renal failure (serum creatinine \>200 mmol/L or eGFR \< 30 ml/min).
* Treatment with Denosumab within the last 12 months. • Have a known hypersensitivity to Denosumab • History of osteonecrosis of the jaw.
* Poor oral hygiene, which is defined as within 3 months of a tooth extraction, dental implants or mandibular surgery
* Planned mandibular surgery or dental implants within the next 12 months.
* Prior non-traumatic vertebral fracture
* Treatment with medication known to affect bones within the last 12 months (such as bisphosphonates, Forsteo®, calcitonin, Protelos®, selective estrogen receptor modulators, glucocorticoids and sex hormones)
* Active or chronic liver disease \*Chronic liver disease is defined as clinical history of decompensated chronic liver disease (ascites, encephalopathy or variceal bleeding) \*Acute Liver disease is defined as an INR of \> 1.5 (in the absence of the use of Warfarin) and AST and ALT \> 2 x ULN
* History of inflammatory arthropathies (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, autoimmune arthropathy)
* Pre-existing medical condition judged to preclude safe participation in the study
* Current treatment with cytotoxic drugs or with systemically administered glucocorticoids
* Abuse of alcohol or drugs, or presence of any condition that in the Investigators opinion may lead to poor adherence to study protocol
* Pregnancy, breast feeding or planning pregnancy or not using adequate contraceptive methods. The following contraceptive products are considered to be safe: Intrauterine devices or hormonal contraception (oral contraceptive pills, implants, transdermal patches, vaginal rings or long-acting injections).
* Likely inability to comply with the visits because of planned activity
* Use of any investigational product with the last month.
* Use of any drug or any other reason which in the Investigator's opinion could interfere with the outcome of the treatment of the acute Charcot foot.
* Cancer, or any clinically significant disease or disorder, except for conditions associated to the diabetes, which in the Investigator's opinion could interfere with the results of the trial
